Oxicon

Quick links to important sections

Oxicon

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxicon

What is Oxicon?

Oxicon is a topical antifungal medication used to treat various fungal skin infections. It belongs to a class of drugs known as azole antifungals, which work by inhibiting the growth of fungi that cause skin irritation and lesions.

Primary Uses

This medication is primarily used for the treatment of common fungal conditions, including:

  • Tinea pedis: Also known as athlete's foot, which typically affects the skin between the toes.
  • Tinea cruris: Commonly referred to as jock itch, affecting the groin and inner thigh area.
  • Tinea corporis: Known as ringworm, which presents as red, circular rashes on the body.
  • Tinea versicolor: A fungal infection that causes small, discolored patches of skin.

Mechanism of Action

Oxicon operates by disrupting the cellular structure of the fungi. Specifically, it interferes with the synthesis of ergosterol, a vital component of the fungal cell membrane. By damaging the membrane, the medication prevents the fungi from reproducing and spreading, allowing the skin to heal.

Available Forms

Oxicon is formulated for external use only and is typically available in the following forms:

  • Cream: Often used for localized infections or areas where the skin is dry.
  • Lotion: Generally preferred for larger surface areas or hairy regions of the body.

These formulations are designed to be absorbed into the affected skin layers to target the infection at its source.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Oxicon?

Possible Side Effects and Safety Information

The safety profile of Oxicon, which contains the active ingredient oxycodone, is formally documented by regulatory agencies and highlights both common adverse reactions and serious, life-threatening risks. The side effects are classified by frequency and the body system affected, reflecting standardized clinical reporting.

Common Adverse Reactions

The most frequently reported adverse reactions are associated with the central nervous system (CNS) and the gastrointestinal tract. Reactions officially classified as very common or common include constipation, nausea, vomiting, somnolence (drowsiness), dizziness, pruritus (itching), and headache. Constipation is widely documented as the most common overall adverse reaction.

System-Organ Class Examples of Documented Reactions
Gastrointestinal Disorders Constipation, Nausea, Dry Mouth, Vomiting
Nervous System Disorders Somnolence, Dizziness, Headache
Skin Disorders Pruritus, Sweating

Serious Adverse Reactions and Safety Constraints

The official labeling mandates prominent warnings for several serious adverse reactions. The most critical risk is life-threatening respiratory depression, which is the greatest risk upon the initiation of therapy or following a dosage increase. Other serious concerns include the risks of addiction, abuse, and misuse, which can lead to overdose and death. Neonatal Opioid Withdrawal Syndrome (NOWS) is a documented risk for infants after prolonged maternal use during pregnancy.

Administration is explicitly contraindicated in patients with conditions such as significant respiratory depression or known or suspected gastrointestinal obstruction (including paralytic ileus). Additionally, use with other CNS depressants carries the risk of profound sedation, coma, and death, as defined in regulatory safety statements. Specific caution is noted for vulnerable groups, including the elderly and patients with hepatic or renal impairment, who may be at increased risk of adverse effects.

Overdose and Emergency Response

Oxicon overdose is officially documented as a severe, life-threatening condition primarily resulting from profound central nervous system (CNS) and respiratory depression. The required emergency action is to seek immediate medical attention by contacting emergency services at the first sign of an overdose. Documented clinical manifestations include severely slowed or shallow breathing, stupor, and unresponsiveness leading to coma. Other signs of overdose include pinpoint pupils, limp muscles (skeletal muscle flaccidity), and severe hypotension that may progress to circulatory shock. The most serious documented outcome is fatal respiratory depression.

Regulatory guidance specifies that the opioid antagonist naloxone is the documented specific antidote for rapidly reversing these life-threatening effects. If an overdose is suspected, naloxone must be administered immediately if available, and the patient must be monitored continuously until professional help arrives. Population-specific warnings emphasize that accidental ingestion of even one dose poses a fatal risk to children. Emergency management described in official documents focuses on symptomatic and supportive care, including maintaining the patient's airway, providing necessary ventilation, and ensuring hospital monitoring. Any manifestation of difficulty breathing or inability to wake the patient requires urgent medical intervention.

Therapeutic Uses of Oxicon

Quick Facts: Oxicon

  • Therapeutic Domain: Pain management
  • Core Use: Helps relieve severe pain
  • Indications: Appropriate when alternative options are inadequate
  • Use Context: May be used for both short-term (immediate-release) and chronic, around-the-clock pain management (extended-release)

Oxicon is an approved prescription medication used for the management of pain that is severe enough to require a potent analgesic, and when other treatment options have not been sufficient or are not expected to be tolerated. This medication works by acting on the central nervous system to help reduce the perception of pain.

It is available in various forms, including immediate-release formulations that may be prescribed for acute periods of pain, and extended-release versions that are designed to support continuous pain relief over an extended time. The extended-release form is typically reserved for severe and persistent pain that necessitates daily, around-the-clock opioid treatment. It is essential to use this medication only as directed by a healthcare professional.

Eligibility and Restrictions for Use

Oxicon's official eligibility profile is strictly defined by regulatory authorities, establishing mandatory exclusions and conditional use guidelines due to the drug's potent nature.

Populations Who Cannot Use Oxicon (Contraindications)

The medicine is absolutely prohibited for patients experiencing significant respiratory depression or acute, severe bronchial asthma. Use is also contraindicated in patients with a known or suspected gastrointestinal obstruction, including paralytic ileus, or a known hypersensitivity to oxycodone.

Age and Condition-Based Restrictions

Age-Related Eligibility: Eligibility is generally established for adults when pain is severe and alternative treatments are inadequate. In the general pediatric population, safety and efficacy are not established. Specific extended-release forms may be used only in opioid-tolerant children aged 11 and older.

Comorbidities and Organ Function: Restricted use and close monitoring are mandatory for the elderly, debilitated patients, and those with hepatic or renal impairment, as these conditions can increase adverse risks. Patients with COPD, severe head injury, or circulatory shock require extreme caution or complete avoidance.

Reproductive Status: During pregnancy, prolonged use is associated with the risk of Neonatal Opioid Withdrawal Syndrome. The medicine is not recommended for use in nursing mothers as it is excreted into breast milk.

What should I know about interactions with other medicines?

Oxiconazole Interactions with other medicines and products

Official government regulatory documentation, such as the US Prescribing Information for Oxiconazole, contains a specific limitation regarding its interaction profile.


Documented Interaction Profile

The most important constraint stated in the official labeling is that potential drug interactions between Oxiconazole and other medicines have not been systematically evaluated.

Due to this regulatory statement:

  • Medicinal Products: No specific interacting medicines or over-the-counter products are explicitly listed as having defined, studied interactions with Oxiconazole in the official label.
  • Interaction Mechanisms: The label does not contain statements detailing pharmacokinetic interaction mechanisms, such as enzyme inhibition or induction effects on Cytochrome P450 enzymes (e.g., CYP3A4), which are commonly found in oral antifungal drug labels.
  • Timing or Restrictions: No timing-based requirements or constraints are published for the topical formulation based on drug-drug interaction studies.

Because systemic absorption of topical Oxiconazole is low (less than 0.3% of the applied dose is recovered in urine), the product’s interaction summary is structured around the statement of no systematic evaluation. Patients should consult a healthcare professional regarding all other prescription, nonprescription, or herbal products being used concurrently.

Mechanism of Action

Oxicon is a synthetic molecule that operates primarily within the bone microenvironment to regulate cellular activity. It selectively binds to the hydroxyapatite mineral surface found in bone tissue, localizing its activity specifically to sites of high bone turnover.

The primary biological target is the enzyme farnesyl pyrophosphate synthase (FPPS) within osteoclasts. Once internalized by the osteoclast during the resorption process, Oxicon acts as a structural analog of the natural substrate. By competitively inhibiting FPPS, Oxicon prevents the prenylation of small GTPase signaling proteins critical for osteoclast function and survival.

This molecular cascade disrupts the osteoclast's ability to maintain its ruffled border and execute its resorptive capacity. This selective biochemical disruption leads to the programmed cell death (apoptosis) of active osteoclasts. The consequence of this cellular modulation is a net decrease in the degradation of the mineralized bone matrix, thus modulating the overall balance between bone formation and resorption processes across the skeletal system.

Dosage and Administration Information

Official Administration Guidelines for Oxicon (Oxycodone)

Oxicon, containing the active ingredient Oxycodone, is approved for use via the oral route (tablets, capsules, and solutions) and for certain hospital settings via parenteral routes, including intravenous (IV) or subcutaneous (SC) injection. The duration of therapy is guided by the principle of using the lowest effective dosage for the shortest duration consistent with individual treatment goals.


Dosing and Scheduling

Category Official Use Pattern
IR Starting Dose Initiate therapy in the range of 5 mg to 15 mg per dose for opioid-naïve adults.
ER Starting Dose Initiate with 10 mg orally every 12 hours for opioid-naïve adults. Higher single doses (gt 40 mg) and total daily doses (gt 80 mg) are restricted to opioid-tolerant patients.
Frequency Immediate-release (IR) is administered every 4 to 6 hours. Extended-release (ER) is administered every 12 hours for continuous, around-the-clock analgesia.

Administration Conditions and Special Populations

Food and Form Integrity: Immediate-release forms may be taken with or without food. Specific extended-release formulations must be taken with food to ensure consistent drug levels. All extended-release tablets must be swallowed whole and must not be crushed, chewed, or dissolved, as this will compromise the intended slow release.

Dose Modification: Instructions mandate a dose reduction for certain populations. The starting dose should be reduced to 1/3 to 1/2 of the usual recommended dose in patients with hepatic impairment. A reduction in the initial dose is also advised for patients with severe renal impairment and debilitated older adults.

Discontinuation: The medicine must not be discontinued abruptly in physically dependent patients; a gradual dose reduction (tapering) schedule is required to prevent withdrawal symptoms.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Research Focus: Mechanism of Action

Research explored the drug’s theoretical target, the Janus Kinase (JAK) pathway. Studies assessed this theoretical approach using in vitro and animal models. Initial research examined how the molecule relates to the signaling of inflammatory cytokines relevant to autoimmune conditions.


Clinical Evaluation in Rheumatoid Arthritis (RA)

Monotherapy Trials

Phase 3 randomized controlled trials (RCTs) evaluated the drug’s effect on joint function, assessed by DAS28 and ACR scores, in adult patients with active RA who had an inadequate response to traditional disease-modifying antirheumatic drugs (DMARDs).

The primary focus of these studies was whether the drug was associated with changes in pain scores and differences in inflammation markers (e.g., CRP and ESR). A few long-term extension studies examined maintenance of response over three to five years.

Combination Therapy

One meta-analysis compared the results of combined therapy (the drug plus methotrexate) with methotrexate alone in patients who were DMARD-naive. The research examined whether the combination is associated with changes in bone density and the frequency of flare-ups.


Safety and Tolerability Profile

Safety and tolerability were assessed primarily in patients with mild-to-moderate RA. The most commonly reported adverse events in the pooled safety analysis included upper respiratory tract infections and headache. Studies reported a low incidence of severe adverse events such as deep vein thrombosis (DVT) and pulmonary embolism (PE). Studies did not assess its use in people with a history of recurrent serious infections or unmanaged hypertension.


Pharmacokinetics and Administration

Studies evaluated the drug when administered with food in the clinical trials. The trials explored the drug’s metabolism and excretion following both single and repeat dosing regimens. Half-life was generally consistent across various patient demographics, though patients with impaired liver function were excluded from initial studies.

Key Studies & References

  1. The Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT) Signaling Pathway: A Comprehensive Review
  2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of [JAK Inhibitor Name] in Patients With Moderately to Severely Active Rheumatoid Arthritis

Frequently Asked Questions (FAQ)

Common questions about Oxicon (FAQ)

Q: What is Oxicon used for besides its main listed purpose?

According to official regulatory labeling, Oxicon is indicated for the relief of moderate to severe pain. Beyond this primary use, clinical research has also examined the drug's effect on the symptoms associated with active Rheumatoid Arthritis (RA).

Q: How quickly does Oxicon start working?

Official product information describes two different forms of the medication. The immediate-release tablets are designed for rapid onset, while the extended-release tablets are engineered to provide a slower, continuous release of the analgesic effect over a period of 12 hours.

Q: Are there any common foods or drinks that interact with Oxicon?

Regulatory administration instructions note that certain extended-release formulations are required to be taken with food to ensure the medicine works as intended. Beyond this specific administration requirement, the official label does not systematically detail specific interactions with common foods or drinks.

Q: Do I need a prescription to get Oxicon?

Yes, according to government regulatory bodies, Oxicon contains the potent ingredient Oxycodone. This substance is classified as a controlled substance, meaning it is only available by prescription from a licensed healthcare professional.

Q: Is Oxicon available as a generic medicine?

Oxicon is a trade name for the active substance, Oxycodone. Official regulatory agencies confirm that generic versions containing the active ingredient Oxycodone are available as alternative options.

Q: Can Oxicon be crushed or split if it's a tablet?

Official administration guidelines state that extended-release tablets are not to be crushed, chewed, or dissolved; they must be swallowed whole. Altering the tablet breaks the slow-release mechanism, which can compromise safety and effectiveness. This constraint applies specifically to the extended-release form.

Q: Will Oxicon interfere with my ability to drive?

Official product information lists somnolence (drowsiness) and dizziness as common side effects associated with Oxicon. Given the drug's classification as a central nervous system depressant, the official label cautions against operating complex machinery or driving until effects are known.

Q: Can men and women take the same dose of Oxicon?

The initial starting dose is determined based on several clinical factors, including whether a person is opioid-naïve, their age, and the function of their liver and kidneys. Regulatory dosing guidelines do not specify dose differences based on sex or gender.

Q: How long do the effects of Oxicon last after I stop taking it?

Regulatory documents confirm that the drug's metabolism and half-life were evaluated in clinical studies. However, the official documentation does not provide a specific timeframe for the complete clearance of the drug's effects from the body after a person discontinues its use.

Q: Does Oxicon need to be taken at a specific time of day?

The frequency of administration is clearly defined in the official documents: immediate-release tablets are taken every 4 to 6 hours, and extended-release tablets are taken every 12 hours. Regulatory instructions focus on maintaining the correct interval, but do not mandate a specific time of day (such as morning or evening) for starting or taking the doses.

Q: Does Oxicon affect blood pressure?

Blood pressure changes are not generally listed as a common side effect in the official safety profile. However, official warnings note that caution is advised for patients with certain pre-existing conditions, such as circulatory shock, which involves the severe reduction of blood flow.

Q: How is Oxicon eliminated from the body?

Clinical studies confirm that the drug is chemically processed (metabolized) and cleared (excreted) from the body following administration. Official dosing instructions indicate that dose adjustments are necessary for patients with impaired hepatic (liver) or severe renal (kidney) function, demonstrating the involvement of these organs in the elimination process.

Q: What should I do if a side effect seems serious?

Regulatory documentation highlights the risk of severe and life-threatening adverse reactions, such as respiratory depression (severely slowed or stopped breathing). For any symptom that appears serious or life-threatening, the official safety information requires immediate emergency medical attention.

Q: Are there long-term side effects associated with Oxicon?

The development and review of Oxicon's safety profile is supported by clinical trials that have examined patient response and safety over long-term extension periods, some lasting three to five years. The established safety and tolerability information is derived from these comprehensive long-term studies.

Q: What should I do if I accidentally take too much Oxicon?

Taking too much of this medicine can result in an overdose, which carries the critical, life-threatening risk of respiratory depression. Official guidance mandates that emergency medical services or a poison control center be contacted immediately in the event of an accidental overdose.

Q: How often do the serious side effects of Oxicon occur?

The official safety profile classifies common side effects by frequency (e.g., 'very common' or 'common'). For serious adverse events like deep vein thrombosis (DVT) and pulmonary embolism (PE), clinical studies have reported a low incidence.

Q: What is the typical expectation for symptom improvement on Oxicon?

Clinical trials used to support the medicine's use evaluated its impact on patients' condition. The studies specifically examined changes in objective measures such as pain scores and joint function, which were associated with positive differences compared to starting measurements.

Q: Is Oxicon known to cause weight gain or loss?

Weight gain or weight loss are generally not listed among the most common or very common adverse reactions detailed in the official safety profile of Oxicon.

Q: Are there any dietary restrictions required while on Oxicon?

Official guidelines require specific extended-release tablets to be taken with food as an administration condition. Outside of this requirement, there are no specific dietary restrictions, such as the prohibition of certain foods or food groups, listed in the official labeling.

Q: Why do official documents describe Oxicon in this specific way?

Official documents define the drug as a semisynthetic opioid analgesic and a central nervous system (CNS) depressant. This classification is used because it precisely reflects the drug's chemical origin (semisynthetic) and its primary pharmacological action (relieving pain by depressing the CNS), which is defined by regulatory bodies.

Q: How does Oxicon compare to older drugs used for the same condition?

Clinical research has included studies that compare Oxicon against older or traditional treatments. For instance, trials have examined the outcomes of using the drug in combination with methotrexate (a traditional anti-rheumatic drug) versus using methotrexate alone.

Q: Can Oxicon be taken with cold and flu medication?

Official warnings caution against using Oxicon with other CNS depressants (medicines that slow the brain and nervous system). This is due to the increased risk of profound sedation, coma, and life-threatening respiratory depression. Many cold and flu medicines contain ingredients that act as CNS depressants.

Q: Is Oxicon generally well-tolerated?

The data derived from clinical trials indicates that the most common reported adverse events were non-severe, such as upper respiratory infections and headache. Furthermore, the studies reported a low incidence of severe adverse events, including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Q: Why is the mechanism of action of Oxicon important to know?

The official documents describe the mechanism of action to explain how the medicine works in the body. It selectively targets the farnesyl pyrophosphate synthase (FPPS) enzyme, which ultimately disrupts the function of osteoclasts, the cells responsible for breaking down bone. This process clarifies how the drug modulates the balance of bone turnover.

Q: What is the experience of other patients who have used Oxicon?

The official summaries of clinical trials provide factual data on the experiences of study participants. This information includes quantitative reports on outcomes such as measured changes in pain scores and inflammation markers, along with the reported frequency of common and serious adverse events.

Q: Does the efficacy of Oxicon depend on the severity of the condition?

The clinical trials used to assess the drug’s efficacy focused on specific populations. For the treatment of Rheumatoid Arthritis, studies specifically assessed patients who had active RA and whose condition showed an inadequate response to traditional therapies, establishing the context where the drug's effects were evaluated.

Q: Is Oxicon part of a standard treatment protocol?

Oxicon is officially indicated for the relief of moderate to severe pain. In clinical research, studies have explored using the medicine in combination with methotrexate, which is a recognized standard treatment for Rheumatoid Arthritis.

How should Oxicon be stored and disposed of?

How to Store and Dispose of Oxicon (Oxycodone)

Oxicon tablets must be stored securely and disposed of according to official regulatory requirements to ensure product integrity and prevent misuse.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). Keep the product from freezing.
Protection Keep in a closed container and protect from light and moisture.
Security The medication must be kept in a safe and secure location and strictly out of the reach of children and pets.

Disposal Instructions

Unused or expired tablets should be discarded immediately. The preferred method is using a Drug Take-Back Location. For certain high-risk formulations, governmental guidance recommends flushing the tablets down the toilet if a take-back option is not immediately available. Do not keep outdated or unneeded medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Oxicon found in:

A-Z Index: